DIRS.INFO The most relevant business & tech news

☆ Stocks to bet on China’s economic future after the real estate pain ends
▼ + stars: | 2023-10-08 | by ( Evelyn Cheng | ) www.cnbc.com time to read: +4 min

For example, China's urbanization rate in 2022 was 64%, the same as Japan's back in the 1960s, she said, noting Japan's urbanization rate in the 1990s was a much higher 77%. China is also leading in innovation based on research and development spending as a percentage of sales, the report said. Easier said than done, especially since that debt and urban development are linked to a struggling real estate sector that's accounted for about a quarter of China's economy. After a summer of mounting worries about China's growth prospects, KKR's head of global macro, Henry McVey, made yet another trip to the region . He pointed to China's push to reduce carbon emissions and increase the integration of tech in the economy — such as through automation.

Persons: Yao Yang, Yao, Bernstein, Rupal Agarwal, Bernstein's Agarwal, BYD — Bernstein, Meituan, Henry McVey, CNBC's Michael Bloom Organizations: Tokyo, CNBC, National School of Development, Peking University, KKR, Citi Locations: China, Japan, Asia, Hong Kong

☆ Bernstein picks recession-beating global stocks for ‘value, growth and quality’
▼ + stars: | 2023-08-03 | by ( Lucy Handley | ) www.cnbc.com time to read: +2 min

Investment bank Bernstein picked a raft of Chinese and Indian stocks in sectors including tech, pharma and IT, naming them on a list of "opportunities for value, growth and quality." "We believe that it is time to increase risk exposure in China by adding more high volatility stocks," the analysts wrote. "GPT can accelerate development of its business and give the company the tailwinds to reshape its strategy," the analysts wrote. Indian stock picks Indian drug company Sun Pharma is also on Bernstein's list of outperform-rated stocks. In India … they have outperformed the market," the analysts wrote, and they also praised Sun's specialty drug portfolio in the U.S.

Persons: Bernstein, Rupal Agarwal, India … Organizations: pharma, " Pharma, Wuxi, Baidu, Sun Pharma, U.S, Infosys, Reliance Industries, New Locations: Asia, China, Wuxi, India, Bangalore, New Commerce

☆ Jumping on the China bandwagon? Analyst reveals whether A-shares or H-shares are a better bet
▼ + stars: | 2023-03-03 | by ( Zavier Ong | ) www.cnbc.com time to read: +2 min

But the euphoria around the reopening has since tapered off, with several key benchmarks in Hong Kong and mainland China paring some of their gains since the beginning of the year. The pullback could be a good opportunity for investors to buy Chinese stocks at more palatable prices, according to Bernstein analyst Rupal Agarwal. A-shares are shares of publicly listed Chinese companies that trade on Chinese stock exchanges. The trading of H-shares is done on the Hong Kong Stock Exchange in Hong Kong dollars. Given China's strict capital controls, A-shares are generally available for trading only to mainland Chinese citizens, while H-shares are more freely tradeable.

☆ Can Chinese stocks rally further? One investment bank thinks so — and names its top stock picks
▼ + stars: | 2023-01-31 | by ( Zavier Ong | ) www.cnbc.com time to read: +3 min

The recovery in Chinese stocks gained steam on Monday, as China's benchmark index came within striking distance of a bull market. Chinese stocks have been buoyed by Beijing's easing of Covid-19 restrictions and a waning regulatory crackdown. "We started the year with an overweight call on China, and while that is a consensus view, there are now concerns on China rally being too sharp/too quick. The extreme inflows in the past 3 months, indeed, pose a threat to the continuity of market rally for next 3 months," Bernstein analyst Rupal Agarwal wrote in a note on Jan. 27. Bernstein's screen for undervalued stocks that have underperformed the market rally tuned up a raft of names.

Search resuls for: "Rupal Agarwal"

4 mentions found